Valvular & structural heart disease
Sarcopenia and frailty in patients undergoing transcatheter aortic valve replacement
Authors' conclusion
The integration of preoperative CT-based SMM to a frailty score significantly improves the prediction of adverse outcomes in patients undergoing TAVR.
Study context
- Population
- Transcatheter aortic valve replacement (TAVR) patients, January–December 2018 (96.7% balloon expandable valves)
- Participants
- 184 patients
- Exposure
- Sarcopenia and frailty markers (sarcopenia, Adapted Green score, Green-SMI score) for predicting adverse outcomes after TAVR
- Outcome
- Composite of:
- Perioperative complications
- Rehospitalization
- Mortality
- Follow-up
- 1 year
Main finding
As reported in the abstract
Composite outcome
Hazard ratio (95% CI)P value
Sarcopeniavs Nonsarcopenic
2.2(1.25–4.02)
P = 0.007Frail (Green-SMI)vs Nonfrail (Green-SMI)
3.4(1.75–6.65)
P < 0.001Observational data: associations, not effects.
Further findings
Prevalence by risk model
- Sarcopenic
- 22.8%
- Frail by Adapted Green score
- 63.6%
- Frail by Green-SMI score
- 53.8%
Original publication
Sarcopenia and frailty in patients undergoing transcatheter aortic valve replacement. Am Heart J. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →